Blood Reviews

Blood Reviews (Blood Rev.) is a review journal in haematology published by Elsevier. Founded in March 1987, it publishes commissioned and invited reviews rather than original research, covers benign and malignant haematology, thrombosis and haemostasis and transfusion medicine, appears six times a year, and had a 2025 impact factor of 7.2.《血液评论》（Blood Reviews''''，缩写 Blood Rev.''）是爱思唯尔出版的血液学综述刊物，1987 年 3 月创刊，只发表约稿与受邀撰写的综述，不涉及原始研究论文。该刊以良性及恶性血液病、血栓与止血、输血医学为主题，现为每年六期，二〇二五年影响因子为 7.2。

Scope

The journal's editorial stance is that a review must be directly usable by the practising haematologist: however complete the material, it has to organise the available evidence on a haematological question into conclusions that support clinical judgement. Coverage runs across the clinical core of haematology and concentrates on:本刊的取稿立场是「为临床血液科医师提供可直接用于诊疗的综述」：一篇稿件不论资料多么完备，都要把某一血液学议题的现有证据梳理成可供临床判断的结论。收文覆盖血液学的临床主干方向，重点包括：

• Benign and malignant haematology: anaemias and red cell disorders, acute and chronic leukaemias, lymphomas and myeloma, and myelodysplastic and myeloproliferative neoplasms.良性与恶性血液病： 贫血与红细胞疾病、急慢性白血病、淋巴瘤与骨髓瘤、骨髓增生异常与骨髓增殖性肿瘤。

• Thrombosis and haemostasis: bleeding disorders and coagulation factor abnormalities, thrombophilia and venous thrombosis, anticoagulant and antiplatelet therapy, and disseminated intravascular coagulation.血栓与止血： 出血性疾病与凝血因子异常、易栓症与静脉血栓、抗凝与抗血小板治疗、弥散性血管内凝血。

• Transfusion medicine: blood groups and matching, transfusion reactions and transfusion safety, blood products and clinical blood use, and patient blood management.输血医学： 血型与配型、输血反应与输血安全、血液制品与临床用血管理、患者血液管理。

• Haematopoietic stem cells and transplantation: indications and conditioning for haematopoietic stem cell transplantation, graft-versus-host disease, and post-transplant complications and long-term follow-up.造血干细胞与移植： 造血干细胞移植的适应证与预处理、移植物抗宿主病、移植后并发症与长期随访。

• Laboratory haematology: cell morphology and peripheral blood interpretation, bone marrow examination, flow cytometry and molecular testing, and quality control in haematology laboratories.实验室血液学： 血细胞形态与外周血判读、骨髓检查、流式细胞术与分子检测、血液学检验的质量控制。

• Infection and immune haematology: infection prevention and treatment in haematology patients, immune cytopenias, haematological toxicity of immunotherapy, and vaccination and immune reconstitution.感染与免疫血液学： 血液科患者的感染防治、免疫性血细胞减少、免疫治疗相关血液学毒性、疫苗接种与免疫重建。

The journal is hybrid and the gold open access article processing charge is 4,910 US dollars. The publisher reports four days to first decision, thirty-one days to a decision after review and 85 days to acceptance, the first-decision figure including editorial screening. The publisher gives an acceptance rate of 85 per cent, a figure that reflects a commissioned review journal and is not comparable with that of a journal taking free submissions.本刊为混合出版，金色开放获取的文章处理费为四千九百一十美元；出版方公布投稿至首次决定四天、复审后决定三十一天、投稿至接收八十五天，其中首次决定包含编辑部初筛；出版方公布的录用比例为百分之八十五，但该比例属约稿型综述刊的口径，与自由投稿刊物不可直接比较。^[1]

History

• Founding (1987): volume 1, issue 1 appeared in March 1987, published by Churchill Livingstone as part of that house's haematology list. The publisher records neither a founder nor a founding rationale.创刊（1987年）： 1987 年 3 月出版第 1 卷第 1 期，创刊时由（Churchill Livingstone）出版并隶属于该社的血液学书系；出版方未记载创刊人与创刊动因。^[2]

• Frequency: the journal began as a quarterly with four issues a year, a pattern retained to volume 18 in 2004. It moved to six issues a year from 2005 to 2018, and since 2019 has appeared as six volumes a year of one issue each, with a corresponding change in volume numbering.刊期沿革： 创刊起为季刊，每年四期，这一形态延续至 2004 年的第 18 卷；2005 年至 2018 年加密为每年六期；2019 年起改为每年六卷、每卷一期，卷号编排方式随之改变。

• Publishing and archiving: the Churchill Livingstone period ran from 1987 to 2019, after which the title was folded into the Elsevier journal portfolio. Back issues are archived long-term by Portico, with coverage reaching back to the first issue.出版与存档： （Churchill Livingstone）时期自 1987 年延续至 2019 年，其后归入爱思唯尔的期刊体系；本刊过刊由（Portico）提供长期存档，早期卷期可回溯至创刊号。

• Metrics and indexing: the impact factor is 7.2 and the CiteScore 12.7. The journal is indexed in Scopus and MEDLINE指标与收录： 影响因子 7.2、引用分数 12.7；本刊被 Scopus 与 MEDLINE 收录，出版方指标页另列 SJR 与 SNIP 而未列科学引文索引扩展版。 the publisher's metrics page also lists SJR and SNIP but does not list the Science Citation Index Expanded.^[1]

Editors

The journal is run by two co-editors-in-chief, based in the United States and the United Kingdom respectively and both specialists in clinical adult haematology, one with an emphasis on haematological oncology. The pairing matches the journal's clinical review remit. The publisher lists past editors by name but gives no tenure years and does not identify the founding editor.本刊现由两名共同主编主持，两人分处美国与英国，分别为成人血液肿瘤与成人血液学的临床专家，这一组合对应本刊「临床综述」的定位；出版方列出历任主编人名但未标注任期年份，也未标明首任主编。^[3]

• Present co-editors-in-chief: Hillard M. Lazarus of Case Western Reserve University works on haematological oncology and haematopoietic stem cell transplantation, and Drew Provan of The Royal London Hospital on adult haematology and immune cytopenias. The publisher does not state the year of either appointment.现任共同主编： （Hillard M. Lazarus）供职于凯斯西储大学，研究方向为血液肿瘤与造血干细胞移植；（Drew Provan）供职于伦敦皇家医院，研究方向为成人血液学与免疫性血细胞减少；出版方未公布两人的就任年份。^[3]

• Past editors: the past editors listed by the publisher are I. Chanarin, I. Franklin, T.P. Baglin, D.C. Linch and J.M. Rowe, all drawn from British haematology. Neither the tenure years nor the identity of the founding editor is published.历任主编： 出版方列出的历任主编依次为（I. Chanarin）、（I. Franklin）、（T.P. Baglin）、（D.C. Linch）与（J.M. Rowe），均为英国血液学界人士；各人任期年份与首任主编人选出版方均未公布。^[3]

• Role in the field: the journal works almost entirely by commission and has long supplied systematic updates to practising and training haematologists学科角色： 本刊以约稿综述为主，长期为血液科医师与培训中的专科医师提供系统性更新，其综述常被引作临床血液学议题的证据梳理来源；因不发表原始研究，其影响因子来自综述的被引表现。 its reviews are frequently cited as syntheses of evidence on clinical haematology topics. Because it publishes no original research, its impact factor rests on citations to its reviews.